Stock Track | Cellebrite Plummets 5% Pre-Market Despite Q2 Beat as Full-Year Guidance Lowered

Stock Track
2025/08/14

Shares of Cellebrite (NASDAQ: CLBT), a leader in digital investigation solutions, plunged 5% in pre-market trading on Thursday following the company's second-quarter earnings release and revised full-year guidance. Despite beating analyst expectations for the quarter, the company's lowered outlook for 2025 appears to have disappointed investors.

Cellebrite reported Q2 revenue of $113.3 million, surpassing the consensus estimate of $112.2 million. The company's adjusted EBITDA of $27.9 million also exceeded expectations of $27 million. However, net income came in at $19.5 million, falling short of the $25.4 million analysts had projected. The mixed results were overshadowed by Cellebrite's decision to lower its full-year 2025 revenue guidance to a range of $465 million to $475 million, down from its previous forecast of $470 million to $485 million.

In conjunction with the earnings report, Cellebrite announced the appointment of Thomas E. Hogan as CEO, effective immediately. Hogan, who had been serving as interim CEO since January 2025, brings over 40 years of technology and software industry experience to the role. While this leadership stability might typically be viewed positively, it appears that investors are more focused on the company's tempered growth expectations for the year, leading to the sharp pre-market decline.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10